Anixa Biosciences is a biotechnology business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.50 – a decrease of 5.66% over the previous week. Anixa Biosciences employs 5 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.50 |
|---|---|
| 52-week range | $2.07 - $4.20 |
| 50-day moving average | $2.76 |
| 200-day moving average | $2.97 |
| Wall St. target price | $9.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.5 from 2025-05-23
| 1 week (2025-05-16) | -5.66% |
|---|---|
| 1 month (2025-04-25) | -9.42% |
| 3 months (2025-02-25) | -15.54% |
| 6 months (2024-11-25) | -22.36% |
| 1 year (2024-05-24) | 3.52% |
|---|---|
| 2 years (2023-05-24) | -25.37% |
| 3 years (2022-05-24) | 3.285 |
| 5 years (2020-05-22) | 14.68% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -38.42% |
| Return on equity TTM | -62.61% |
| Profit margin | 0% |
| Book value | $0.55 |
| Market Capitalization | $80.5 million |
TTM: trailing 12 months
We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.
Anixa Biosciences's shares were split on a 1:25 basis on 25 June 2015 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anixa Biosciences shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Anixa Biosciences shares which in turn could have impacted Anixa Biosciences's share price.
Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $2.07 up to $4.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 0.435. This would suggest that Anixa Biosciences's shares are less volatile than average (for this exchange).
Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.